UNSPSC 51101926: Chloroguanide

This classification denotes a dihydrofolate reductase inhibitor and antimalarial agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6T04V14CU9. European Medicines Agency schedules Chloroguanide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04062MIG. Chloroguanide hydrochloride generally arises in the molecular formula C11H17CL2N5. The term 'chloroguanide hydrochloride' is a United States Adopted Name designation. SMILES: CLC1CC(N(/C(=N/C(C)C)N)C(=N)N)CCC1CL.CL.

UNSPSC 51101926 Chloroguanide, a Commodity code, shows minimal alignment between its nominal scope and recent state and local procurement activity. The code nominally designates an antimalarial pharmaceutical compound, yet recent solicitations tagged under it reflect a broader demand for pharmaceuticals, emergency medical supplies, and pharmacy benefit program administration rather than chloroguanide specifically. State and local governments are procuring naloxone and drug deactivation systems, medical and first aid supplies for fire-rescue operations, generic multi-source pharmaceuticals through cooperative purchasing vehicles, and pharmacy benefit management services—none of which are chloroguanide products. The issuing bodies include county health departments (Seminole County, Florida), municipal fire departments (City of Tampa), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local facilities across Minnesota and Oregon). This mix reflects the fragmented nature of pharmaceutical procurement across health, safety, and benefit administration functions at different government levels.

Recent opportunities span Florida, Texas, Minnesota, and Oregon, with no geographic concentration evident in the limited sample. Representative solicitations include Seminole County's IFB for naloxone and drug deactivation systems (1,900 units and 800 units annually, due July 26, 2023), the City of Tampa's IFB for medical and first aid supplies for its Fire Department Rescue Division (169 line items, estimated contract amount $700,000, SLBE set-aside with 5% discount, due March 13, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across cooperative members (proposals due March 26, 2026, with June 1, 2026 implementation). The Texas HHS Commission also issued an RFI on direct-to-manufacturer prescription programs (due April 3, 2026), signaling emerging state interest in alternative pharmacy benefit contracting models. The code appears to capture pharmaceutical and medical-supply procurement broadly rather than chloroguanide as a discrete product line, suggesting either miscoding of opportunities or obsolescence of the code's nominal scope in state and local procurement systems.